Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2004

View Archived Issues

Effective cytolysis of Hodgkin's lymphoma tumor cells by antibody-cytokine fusion protein

Phase II study of GDNF for Parkinson's fails to meet primary endpoint

Priority review and accelerated approval designations for Antegren BLA

Aplidin receives orphan drug status for ALL

NX-1207 shows potential as a front-line treatment for BPH in phase I/II trials

FDA accepts IND for MN-029

Fast track status for INO-1001 for patients with STEMI

IND accepted for phase II trials of ORG-25969

Favorable results for ACP-103 for use in Parkinson's patients

Exelixis submits IND for XL-999

Europe's CHMP hands down positive opinion for MabThera in indolent NHL

Bionomics progress in gene test for epilepsy

Retinoic metabolism inhibitors promising against prostate cancer

Novel SERM with minimal ovarian effects

New melatonin receptor ligands prepared and tested by French scientists

Novel modulators of nAChR and monoamine receptors or transporters claimed by NeuroSearch

Servier researchers describe novel cognition-enhancing agents

New IGF-1R inhibitors with potential in cancer therapy

Novel topoisomerase inhibitors identified by researchers at State U. of New Jersey

Novel fusion-targeting antiviral agents presented by Trimeris

New MCH receptor modulators in early development at Tularik

Femara sNDA granted priority review by FDA

Erbitux receives E.U. approval for metastatic colorectal cancer

FDA clears IND for study of VPI-013 in patients with major depressive disorder

IND submission to start phase I trial of thrombin inhibitor ARC-183

Enrollment open in phase III trial of Veronate

Tularik stockholders to meet in August to vote on acquisition by Amgen

Arava approved in Europe for active psoriatic arthritis

Vasopressin V2 receptor antagonist effective aquaretic in vivo

PXD-101 enters phase I trial in hematologic cancer

Exenatide NDA submission for type 2 diabetes

Selective glucocorticoid receptor modulator may prevent progression of multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...